Jaap C Reijneveld

List of Publications by Year
in descending order

59 papers	**4,116** citations	147801 **31** h-index	149698 **56** g-index
61 all docs	**61** docs citations	**61** times ranked	**7420** citing authors

#	Article	IF	Citations
1	Another look at floor and ceiling effects in the EORTC QLQ–C30 Physical Functioning subscale and possible solutions. Cancer, 2022, 128, 2384-2385.	4.1	1
2	Clustering of EORTC QLQ-C30 health-related quality of life scales across several cancer types: Validation study. European Journal of Cancer, 2022, 170, 1-9.	2.8	6
3	Advance care planning (ACP) in glioblastoma patients: Evaluation of a disease-specific ACP program and impact on outcomes. Neuro-Oncology Practice, 2022, 9, 496-508.	1.6	3
4	A Web-Based Lifestyle Intervention Aimed at Improving Cognition in Patients With Cancer Returning to Work in an Outpatient Setting: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2021, 10, e22670.	1.0	3
5	Spatial concordance of DNA methylation classification in diffuse glioma. Neuro-Oncology, 2021, 23, 2054-2065.	1.2	19
6	Tumor-Educated Platelet RNA for the Detection and (Pseudo)progression Monitoring of Glioblastoma. Cell Reports Medicine, 2020, 1, 100101.	6.5	52
7	Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms. Journal of Neuro-Oncology, 2020, 147, 485-494.	2.9	16
8	International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium. Lancet Oncology, The, 2020, 21, e83-e96.	10.7	180
9	Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients. EJNMMI Research, 2019, 9, 57.	2.5	8
10	The association between preoperative edema and postoperative cognitive functioning and health-related quality of life in WHO grade I meningioma patients. Acta Neurochirurgica, 2019, 161, 579-588.	1.7	20
11	Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419).. Journal of Clinical Oncology, 2019, 37, 2056-2056.	1.6	3
12	EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.. Journal of Clinical Oncology, 2019, 37, TPS2072-TPS2072.	1.6	6
13	Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. Lancet Oncology, The, 2018, 19, e173-e180.	10.7	32
14	The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033. Acta Neuropathologica, 2018, 135, 601-615.	7.7	76
15	Internet-based guided self-help for glioma patients with depressive symptoms: a randomized controlled trial. Journal of Neuro-Oncology, 2018, 137, 191-203.	2.9	46
16	Cognitive functioning and functional brain networks in postoperative WHO grade I meningioma patients. Journal of Neuro-Oncology, 2018, 140, 605-613.	2.9	17
17	Statistical analysis of patient-reported outcome data in randomised controlled trials of locally advanced and metastatic breast cancer: a systematic review. Lancet Oncology, The, 2018, 19, e459-e469.	10.7	66
18	The EORTC CAT Core—The computer adaptive version of the EORTC QLQ-C30 questionnaire. European Journal of Cancer, 2018, 100, 8-16.	2.8	68

#	ARTICLE	IF	CITATIONS
19	Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire. Health and Quality of Life Outcomes, 2018, 16, 114.	2.4	133
20	Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. Lancet Oncology, The, 2018, 19, 1170-1179.	10.7	80
21	Localization of the Epileptogenic Zone Using Interictal MEG and Machine Learning in a Large Cohort of Drug-Resistant Epilepsy Patients. Frontiers in Neurology, 2018, 9, 647.	2.4	39
22	Oscillatory brain activity associates with neuroligin-3 expression and predicts progression free survival in patients with diffuse glioma. Journal of Neuro-Oncology, 2018, 140, 403-412.	2.9	31
23	Altered $GABA_A$ receptor density and unaltered blood–brain barrier [^{11}C]flumazenil transport in drug-resistant epilepsy patients with mesial temporal sclerosis. Journal of Cerebral Blood Flow and Metabolism, 2017, 37, 97-105.	4.3	8
24	Dynamic hub load predicts cognitive decline after resective neurosurgery. Scientific Reports, 2017, 7, 42117.	3.3	39
25	Connectomic profile and clinical phenotype in newly diagnosed glioma patients. NeuroImage: Clinical, 2017, 14, 87-96.	2.7	64
26	Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. American Journal of Neuroradiology, 2017, 38, 1884-1891.	2.4	42
27	Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis. Journal of Neuro-Oncology, 2017, 135, 183-192.	2.9	138
28	Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell, 2017, 32, 238-252.e9.	16.8	235
29	Impact of neurocognitive deficits on patient–proxy agreement regarding health-related quality of life in low-grade glioma patients. Quality of Life Research, 2017, 26, 869-880.	3.1	29
30	Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. Neuro-Oncology, 2017, 19, 12-21.	1.2	94
31	Identifying the epileptogenic zone in interictal resting–state MEG source–space networks. Epilepsia, 2017, 58, 137-148.	5.1	76
32	Final results of the EORTC Brain Tumor Group randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1st recurrence grade II/III glioma without 1p/19q co-deletion.. Journal of Clinical Oncology, 2017, 35, 2009-2009.	1.6	8
33	Advance Care Planning in Glioblastoma Patients. Cancers, 2016, 8, 102.	3.7	39
34	Psycho-oncology. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 305-313.	1.8	0
35	Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma. Journal of Neuro-Oncology, 2016, 129, 221-230.	2.9	13
36	Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. Lancet Oncology, The, 2016, 17, e510-e514.	10.7	158

#	ARTICLE	IF	CITATIONS
37	Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials—Letter. Clinical Cancer Research, 2016, 22, 5617-5617.	7.0	18
38	Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study). Neurosurgery, 2016, 79, 535-540.	1.1	19
39	Health-related quality of life in brain tumor patients: as an endpoint in clinical trials and its value in clinical care. Expert Review of Quality of Life in Cancer Care, 2016, 1, 37-44.	0.6	14
40	Antiepileptic drug treatment in the end-of-life phase of glioma patients: a feasibility study. Supportive Care in Cancer, 2016, 24, 1633-1638.	2.2	34
41	Attitudes and preferences toward monitoring symptoms, distress, and quality of life in glioma patients and their informal caregivers. Supportive Care in Cancer, 2016, 24, 3011-22.	2.2	23
42	Seizure reduction is a prognostic marker in low-grade glioma patients treated with temozolomide. Journal of Neuro-Oncology, 2016, 126, 347-354.	2.9	31
43	Effect of the European Organization for Research and Treatment of Cancer (EORTC) on social life for cancer survivors in Europe.. Journal of Clinical Oncology, 2016, 34, 218-218.	1.6	0
44	Health-Related Quality of Life in Stable, Long-Term Survivors of Low-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1023-1029.	1.6	64
45	Quantification of ^{11}C-Laniquidar Kinetics in the Brain. Journal of Nuclear Medicine, 2015, 56, 1730-1735.	5.0	5
46	The impact of bevacizumab on health-related quality of life in patients treated for recurrent glioblastoma: Results of the randomised controlled phase 2 BELOB trial. European Journal of Cancer, 2015, 51, 1321-1330.	2.8	45
47	Seizure outcome after radiotherapy and chemotherapy in low-grade glioma patients: a systematic review. Neuro-Oncology, 2015, 17, 924-934.	1.2	65
48	RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell, 2015, 28, 666-676.	16.8	700
49	Learning of anticipatory responses in single neurons of the human medial temporal lobe. Nature Communications, 2015, 6, 8556.	12.8	48
50	Allowance of tumor-educated platelets for multiclass liquid biopsy-based diagnosis of cancer.. Journal of Clinical Oncology, 2015, 33, 11058-11058.	1.6	0
51	Patients' Preferences for Participation in Treatment Decision-Making at the End of Life: Qualitative Interviews with Advanced Cancer Patients. PLoS ONE, 2014, 9, e100435.	2.5	79
52	The association between cognitive functioning and health-related quality of life in low-grade glioma patients. Neuro-Oncology Practice, 2014, 1, 40-46.	1.6	37
53	Epilepsy in the end of life phase of brain tumor patients: a systematic review. Neuro-Oncology Practice, 2014, 1, 134-140.	1.6	21
54	DNA copy number analysis of fresh and formalin-fixed specimens by shallow whole-genome sequencing with identification and exclusion of problematic regions in the genome assembly. Genome Research, 2014, 24, 2022-2032.	5.5	362

#	ARTICLE	IF	CITATIONS
55	Epilepsy surgery outcome and functional network alterations in longitudinal MEG: A minimum spanning tree analysis. NeuroImage, 2014, 86, 354-363.	4.2	113
56	The level of patient-reported outcome reporting in randomised controlled trials of brain tumour patients: A systematic review. European Journal of Cancer, 2014, 50, 2432-2448.	2.8	47
57	Health-Related Quality of Life or Quantity of Life: A Difficult Trade-Off in Primary Brain Tumors?. Seminars in Oncology, 2014, 41, 541-552.	2.2	25
58	The application of graph theoretical analysis to complex networks in the brain. Clinical Neurophysiology, 2007, 118, 2317-2331.	1.5	494
59	CAV3 gene mutation analysis in patients with idiopathic hyper-CK-emia. Muscle and Nerve, 2006, 34, 656-658.	2.2	24